DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury.

"Following the successful completion of our Phase 1 oral, single-dose study of DUR-928, we have now begun enrollment for a Phase 1 multiple-ascending-dose trial," said James E. Brown, President and CEO of DURECT. "This trial will provide valuable information on multi-dose pharmacokinetics that will be important as we continue moving toward Phase 2 planned for next year."

Source:

DURECT Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study reveals intricate pathway that dictates the cell’s ability to be resilient and plastic